The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence.
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
The cognitive benefits of modafinil to patients undergoing 7-day inpatient withdrawal from methamphetamine (MA) dependence were examined as part of a double-blind, randomized, placebo-controlled pilot trial. Recent evidence has identified modafinil-related improvements in treatment outcomes for MA-dependent patients; however, the benefits to cognition function, which is critical to treatment success but known to be impaired, has yet to be examined. The first 20 participants recruited to the study were administered either 200 mg of modafinil (once daily) or placebo, and a neuropsychological test battery (including an MA version of the emotional Stroop task) at admission (n = 17) and discharge (n = 14). Follow-up interviews were conducted at 1-month postdischarge (n = 13). After participant withdrawals (3 in each group), treatment was associated with a significant improvement in immediate verbal memory recall and nonsignificant trend toward improvement on executive function and delayed memory tasks. No benefit was seen for measures of verbal learning, visual memory, processing speed, or verbal fluency. All participants showed a significant attentional bias for MA-related stimuli on the emotional Stroop task. The magnitude of bias predicted both retention in treatment and relapse potential at follow-up but was not significantly ameliorated by modafinil treatment. While nonsignificant, the effect sizes of modafinil-related improvements in executive function and memory were consistent with those found in more robustly powered studies of cognitive benefits in attention-deficit/hyperactivity disorder and schizophrenia, supporting the need for further research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Seven days of modafinil (200 mg/d) increased measures of verbal recall (65).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“nonsignificant -but improved- executive function and delayed memory tasks compared to placebo.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Hester, R. et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“Significantly improved verbal recall”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Hester, R. et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757
Attentional bias in addictive behaviors: A review of its development, causes, and consequences
FIELD, M., & COX, W. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.030 · Cited by 1,376
The Journal of Neuropsychiatry and Clinical Neurosciences
Bowden, V. M. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490110111047 · Cited by 1,223
Association of Dopamine Transporter Reduction With Psychomotor Impairment in Methamphetamine Abusers
Volkow, N. D., Chang, L., Wang, G.-J., Fowler, J. S., Leonido-Yee, M., Franceschi, D., Sedler, M. J., Gatley, S. J., Hitzemann, R., Ding, Y.-S., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.377 · Cited by 984
Structural Abnormalities in the Brains of Human Subjects Who Use Methamphetamine
Thompson, P. M., Hayashi, K. M., Simon, S. L., Geaga, J. A., Hong, M. S., Sui, Y., Lee, J. Y., Toga, A. W., Ling, W., & London, E. D. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0713-04.2004 · Cited by 760 · cited 2×
“MA-related cognitive deficits have also been linked to a variety of cortical differences between MA users and matched controls, including fronto-cortical dysfunction (London et al., 2005; Monterosso et al., 2007; Paulus, Tapert, & Schuckit, 2005; Thompson, 2004), dopaminergic transporter levels (Mccann et al.”
BackgroundLoss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence
Volkow, N. D., Chang, L., Wang, G.-J., Fowler, J. S., Franceschi, D., Sedler, M., Gatley, S. J., Miller, E., Hitzemann, R., Ding, Y.-S., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09414.2001 · Cited by 754
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713
Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis
Scott, J. C., Woods, S. P., Matt, G. E., Meyer, R. A., Heaton, R. K., Atkinson, J. H., & Grant, I. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9031-0 · Cited by 671 · cited 1×
“The neuropsychological performance of the current sample is also consistent with previous evidence of cognitive deficits observed in active and abstinent MA users (for reviews, see Meredith, Jaffe, & Ang-Lee, 2005; Nordahl, Salo, & Leamon, 2003; Scott et al., 2007), particularly in the domains of memory and learning (…”
ResultField, M., Munafò, M. R., & Franken, I. H. A. (2009) · Psychological Bulletin · doi:10.1037/a0015843 · Cited by 602
Volkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G.-J., Jayne, M., Hooker, J. M., Wong, C., et al. (2009) · JAMA · doi:10.1001/jama.2009.351 · Cited by 529 · cited 1×
“, 2006), and resulting in increased extracellular dopamine in cortical regions critical to cognition (Volkow et al., 2009).”
Background
Cited by
Cognitive enhancement as a treatment for drug addictions
Sofuoglu, M., DeVito, E. E., Waters, A. J., & Carroll, K. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.021 · Cited by 298
“inpatient study, 7 days of modafinil treatment improved immediate verbal memory function (Hester et al., 2010).”
BackgroundMereu, M., Bonci, A., Newman, A. H., & Tanda, G. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3232-4 · Cited by 148
“…subjects, none of them found statistically significant improvements in urine detection of metabolites, abstinence, depressive symptoms, or craving (Anderson et al. 2012; De La Garza et al. 2010; Heinzerling et al. 2010; Hester et al. 2010; Lee et al. 2013; McGaugh et al. 2009; Shearer et al. 2009).”
Barriers to accessing methamphetamine treatment: A systematic review and meta-analysis
Cumming, C., Troeung, L., Young, J. T., Kelty, E., & Preen, D. B. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.10.001 · Cited by 131
Neuropsychological Consequences of Chronic Drug Use: Relevance to Treatment Approaches
Cadet, J. L., & Bisagno, V. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00189 · Cited by 129
“org METH use increase the risk of poorer health outcomes, high-risk behaviors, treatment non-adherence, and repeated relapses (110, 118).”
BackgroundCognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders
Sofuoglu, M., DeVito, E. E., Waters, A. J., & Carroll, K. M. (2016) · Journal of Dual Diagnosis · doi:10.1080/15504263.2016.1146383 · Cited by 109
“Findings suggest a strong attentional bias to cocaine (see Leeman, Robinson, Waters, & Sofuoglu, 2014 for a review) and methamphetamine cues (Hester et al., 2010).”
BackgroundAcute Modafinil Effects on Attention and Inhibitory Control in Methamphetamine-Dependent Humans
Dean, A. C., Sevak, R. J., Monterosso, J. R., Hellemann, G., Sugar, C. A., & London, E. D. (2011) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2011.72.943 · Cited by 79
“…study, immediate verbal memory was improved in MA-dependent participants receiving modafi nil (200 mg; n = 7) relative to those receiving placebo (n = 7) (Hester et al., 2010), but differences between the groups were not observed on measures of visual memory, processing speed, or verbal fl uency.”
BackgroundAnderson, A. C., Youssef, G. J., Robinson, A. H., Lubman, D. I., & Verdejo‐García, A. (2021) · Addiction · doi:10.1111/add.15469 · Cited by 80
González, B., Raineri, M., Cadet, J. L., García‐Rill, E., Urbano, F. J., & Bisagno, V. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.02.002 · Cited by 63
“Recent clinical studies showed that modafinil oral administration in METH users with 7 days of abstinence, at a dose recommended for the treatment of sleeping disorders (200 mg, once daily), although improved several domains of executive function, had no effect on visual memory performance (Hester et al., 2010).”
BackgroundAcheson, L. S., Williams, B. H., Farrell, M., McKetin, R., Ezard, N., & Siefried, K. J. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13511 · Cited by 52
Wodarz, N., Krampe-Scheidler, A., Christ, M., Fleischmann, H., Looser, W., Schoett, K., Vilsmeier, F., Bothe, L., Schaefer, C., & Gouzoulis-Mayfrank, E. (2017) · Pharmacopsychiatry · doi:10.1055/s-0042-123752 · Cited by 40
“For other stimulants, either no evidence was available for the acute treatment of methamphetamine-dependent users (methyl - phenidate), or the available studies did not show any effects or they only showed marginal benefits compared to placebo [32–36].”
BackgroundMethamphetamine Toxicities and Clinical Management
Coffin, P. O., & Suen, L. W. (2023) · NEJM Evidence · doi:10.1056/evidra2300160 · Cited by 44
Clinical management of psychostimulant withdrawal: review of the evidence
Li, M. J., & Shoptaw, S. J. (2023) · Addiction · doi:10.1111/add.16093 · Cited by 39
Härtel-Petri, R., Krampe-Scheidler, A., Braunwarth, W.-D., Havemann-Reinecke, U., Jeschke, P., Looser, W., Mühlig, S., Schäfer, I., Scherbaum, N., Bothe, L., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-105500 · Cited by 39
Pérez de los Cobos, J., Siñol, N., Pérez, V., & Trujols, J. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12045 · Cited by 35
Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups
Soares, E. F. P., & Pereira, F. C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1681970 · Cited by 34
“[29] reported that informal discussions with the FDA suggested 75% compliance as adequate treatment adherence.”
BackgroundNuijten, M., Blanken, P., van den Brink, W., Goudriaan, A. E., & Hendriks, V. M. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645268 · Cited by 34
“Modafinil improved verbal memory recall after 5 days of administration (Hester et al., 2010); and modafinil-related improvements in working memory were found in a subgroup of methamphetamine-dependent volunteers with poor baseline performance, as compared with high performers, after 3 days of administration (Kalechste…”
ResultPharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets
Yates, J. R. (2024) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s431273 · Cited by 32
Dean, A. C., Nurmi, E. L., Moeller, S. J., Amir, N., Rozenman, M. S., Ghahremani, D. G., Johnson, M., Berberyan, R., Hellemann, G. S., Zhang, Z., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5100-8 · Cited by 28
Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?
Hersey, M., Bacon, A. K., Bailey, L. G., Coggiano, M. A., Newman, A. H., Leggio, L., & Tanda, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.656475 · Cited by 25
Medications between psychiatric and addictive disorders
Lalanne, L., Lutz, P.-É., Trojak, B., Lang, J.-P., Kieffer, B. L., & Bacon, É. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.10.009 · Cited by 26
Alleva, L., Tirelli, E., & Brabant, C. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.025 · Cited by 25
Modafinil, an atypical CNS stimulant?
Hersey, M., & Tanda, G. (2023) · Advances in pharmacology · doi:10.1016/bs.apha.2023.10.006 · Cited by 23
Wu, M., Satogami, K., Liang, C., Stubbs, B., Carvalho, A. F., Brunoni, A. R., Su, K., Tu, Y., Wu, Y., Chen, T., et al. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13452 · Cited by 17
Moosavi, S. M., Charati, J. Y., & Amini, F. (2019) · PubMed Central · doi:10.22122/ahj.v11i3.219 · Cited by 14
Lim, A. C., Grodin, E. N., Green, R., Venegas, A., Meredith, L. R., Courtney, K. E., Moallem, N. R., Sayegh, P., London, E. D., & Ray, L. A. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1741002 · Cited by 14
Executive Dysfunction in Addiction
Jarmolowicz, D. P., Mueller, E. T., Koffarnus, M. N., Carter, A. E., Gatchalian, K. M., & Bickel, W. K. (2013) · Wiley eBooks · doi:10.1002/9781118384404.ch2 · Cited by 14
Memory impairment induced by amphetamine derivatives in laboratory animals and in humans: a review
Camarasa, J., Rodrigo, T., Pubill, D., & Escubedo, E. (2011) · BioMolecular Concepts · doi:10.1515/bmc.2011.048 · Cited by 13
Peters, M. S., Park, C. H. J., Turner, A., Guerin, A. A., & Kim, J. H. (2023) · Addiction Neuroscience · doi:10.1016/j.addicn.2023.100064 · Cited by 11
Fitzpatrick, R. E., Robinson, A. H., Rubenis, A. J., Lubman, D. I., & Verdejo‐García, A. (2021) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1869243 · Cited by 11
“For example, three studies lacked a healthy control comparison group (15,23,24) and one other study had high rates of individuals with ADHD in the sample (23).”
BackgroundPharmacological cognitive enhancers
Peltier, M. R., & Sofuoglu, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815298-0.00023-x · Cited by 10
Management of withdrawal from alcohol and other drugs
Lintzeris, N., Sunjic, S., Demirkol, A., Branezac, M., Ezard, N., Siefried, K. J., Acheson, L. S., Bascombe, F., Tremonti, C., & Haber, P. (2019) · doi:10.57022/mjjp9930 · Cited by 10
Makarenko, I., Mahroug, A., Jutras‐Aswad, D., Larney, S., Martel‐Laferrière, V., & Bruneau, J. (2025) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-025-01537-8 · Cited by 10
“In RCTs of treatments with modafinil (Canavan et al., 2014; Hester et al., 2010; Nuijten et al., 2016), citalopram (Schmitz et al., 2009), topiramate (Johnson et al., 2007), atomoxetine (Lim et al., 2024) and a detoxifying program (Vilaprino et al., 2024), findings demonstrated mixed effects of…”
Regier, P. S., Kampman, K. M., & Childress, A. R. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_303 · Cited by 7
Modafinil for the Treatment of Methamphetamine Dependence
Lashkaripour, K., Adibi, A., Mashhadi, F. F., & Dashipour, A. (2016) · international journal high risk behaviors & addiction · doi:10.5812/ijhrba.37660 · Cited by 1
Evaluation of Modafinil in Preclinical Behavioral Assays of Abuse Liability
Quisenberry, A. J. (2013) · ScholarWorks - WMU (Western Michigan University)
Pharmacological Treatment for Methamphetamine Dependence
Culver, B. E. (2014) · Research Exchange (Washington State University)
Boosting impulse control in addiction. Pharmacological neuroimaging studies
Schmaal, L. (2013) · UvA-DARE (University of Amsterdam)
REINFORCING, SUBJECTIVE, AND COGNITIVE EFFECTS OF METHAMPHETAMINE DURING D- AMPHETAMINE MAINTENANCE
Pike, E. (2013) · UKnowledge (University of Kentucky)
Nuijten, M. (2017) · Leiden Repository (Leiden University) · Cited by 1
Pharmacological Treatments for Methamphetamine Use Disorder: A Systematic Review
Evans, J. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/q5np-jm02
Wodarz, N., Christ, M., Fleischmann, H., Looser, W., Schoett, K., Vilsmeier, F., Krampe-Scheidler, A., Schaefer, C., Bothe, L., Mühlig, S., et al. (2019) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000615
Learning mechanisms of addiction
Yates, J. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90578-7.00005-0
Salience attribution in addiction and psychosis
Freeman, T. P. (2013) · UCL Discovery (University College London)
Metadata
- Authors
- Hester, R., Lee, N., Pennay, A., Nielsen, S., & Ferris, J.
- Affiliations
- The University of Melbourne (AU)
- Venue
- Experimental and Clinical Psychopharmacology
- Published
- 2010-12
- Volume
- 18
- Issue
- 6
- Pages
- 489-497
- ISSN
- 1064-1297 (ISSN-L)
- 1936-2293
- OpenAlex
- W2134746607
- Cited by
- 42
- References
- 68
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 6 · 2018: 1 · 2017: 3 · 2016: 5 · 2015: 1 · 2014: 2 · 2013: 6 · 2012: 3
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental and Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Australian Government Department of Health and Ageing
- National Health and Medical Research Council (519730)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Keywords
- modafinil, methamphetamine dependence, attentional bias, emotional Stroop task, neuropsychological performance, verbal memory, executive function, treatment retention, relapse, cognitive impairment
- MeSH terms
- Modafinil, Adult, Central Nervous System Stimulants, Attention, Benzhydryl Compounds, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Memory, Methamphetamine, Middle Aged, Neuropsychological Tests, Pilot Projects, Recurrence, Substance Withdrawal Syndrome, Treatment Outcome, Amphetamine-Related Disorders, Young Adult, Executive Function, Stroop Test
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.